ELSEVIER

International Journal of Antimicrobial Agents 15 (2000) 323–325

INTERNATIONAL JOURNAL OF
Antimicrobial Agents

www.ischemo.org

Author index

Volume 15 (2000)

Abad, F., F. Calbo, P. Zapater, F. Rodríguez-Vilanova, L.-E. García-Pérez and J.A. Sacristán, Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients **15**, 65
Algün, Ü., see Tünger, Ö. **15**, 131
Al-Haddad, A., see Udo, E.E. **15**, 19
Allen, A., E. Bygate, H. Faessel, L. Isaac and A. Lewis, The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers **15**, 283
Alvarez, C., see Ortega, E. **15**, 193
Araque, M., B. Nieves, L. Lauretti and G.M. Rossolini, Molecular basis of extended-spectrum β-lactamase production in nosocomial isolates of *Klebsiella pneumoniae* from Mérida, Venezuela **15**, 37
Ascioglu, S., B.E. de Pauw and J.F.G.M. Meis, Prophylaxis and treatment of fungal infections associated with haematological malignancies **15**, 159
Atman, Ü.C., see Tünger, Ö. **15**, 131

Ballesta, S., see García, I. **15**, 201
Baquero, F., see Torres, C. **15**, 257
Bartoloni, A., see Nicoletti, G. **15**, 265
Blondeau, J.M. and D. Vaughan, In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres **15**, 213
Bonfiglio, G., see Nicoletti, G. **15**, 265
Bouza, E., see Muñoz, P. **15**, 83
Brade, V., see Hunfeld, K.-P. **15**, 11
Bravo, M., see Herrera, M. **15**, 305
Brenciaglia, M.I., see Sisto, F. **15**, 277
Bujdáková, H., see Múčková, M. **15**, 153
Burillo, A., see Muñoz, P. **15**, 83
Bygate, E., see Allen, A. **15**, 283

Cage, G.D., see Pettit, R.K. **15**, 299
Calbo, F., see Abad, F. **15**, 65
Carrión, P., see Herrera, M. **15**, 305
Castillo, A., see Herrera, M. **15**, 305
Castillo, J., see del Campo, R. **15**, 221
Chiba, S., see Numazaki, K. **15**, 241

Dagan, R., see Leibovitz, E. **15**, 169
Davis, E., see Zheng, X. **15**, 231
de Cienfuegos, G.A., see Ortega, E. **15**, 193
del Campo, R., C. Tenorio, C. Rubio, J. Castillo, C. Torres and R. Gómez-Lus, Aminoglycoside-modifying enzymes in high-level streptomycin and gentamicin resistant *Enterococcus* spp. in Spain **15**, 221
De Logu, A., A.M. Fadda, M.L. Pellerano, G. Diana and M.L. Schivo, Prevention by L-α-phosphatidylcholine of antifungal activity in vitro of liposome-encapsulated imidazoles determined by using time-killing curves **15**, 43
de Pablo, M.A., see Ortega, E. **15**, 193
de Pauw, B.E., see Ascioglu, S. **15**, 159
Deshpande, L., M.A. Pfaller and R.N. Jones, In vitro activity of ceftiofur tested against clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* including extended spectrum β-lactamase producing strains **15**, 271
Diana, G., see De Logu, A. **15**, 43
Dinç, G., see Tünger, Ö. **15**, 131
Domínguez, L., see Teshager, T. **15**, 137
Dubini, F., see Sisto, F. **15**, 277

Egerer, G., H. Goldschmidt, H. Salwender, U. Hegenbart, I. Ehrhard, R. Haas and A.D. Ho, Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation **15**, 119
Ehrhard, I., see Egerer, G. **15**, 119
El-Zaatari, F.A.K., see Kwon, D.H. **15**, 31
Emanuele, M.R., see Jagannath, C. **15**, 55
Errecalde, C., see García Ovando, H. **15**, 77
Erwin, M.E., see Jones, R.N. **15**, 227

Fadda, A.M., see De Logu, A. **15**, 43
Faessel, H., see Allen, A. **15**, 283
Falagas, M.E. and E. Siakavellas, *Bacteroides*, *Prevotella*, and *Porphyromonas* species: a review of antibiotic resistance and therapeutic options **15**, 1
Farinati, A., see Quiroga, M. **15**, 243

Gaforio, J.J., see Ortega, E. **15**, 193
Gallego, A.M., see Ortega, E. **15**, 193
García, I., A. Pascual, S. Ballesta and E.J. Perea, Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells **15**, 201
García Ovando, H., N. Gorla, G. Poloni, N. Trotti, G. Prieto and C. Errecalde, Intravenous pharmacokinetics of ciprofloxacin in goats **15**, 77
García-Pérez, L.-E., see Abad, F. **15**, 65
Garde, J., see Teshager, T. **15**, 137
Gnanou, J.C. and P. Sanders, Antibiotic resistance in bacteria of animal origin: methods in use to monitor resistance in EU countries **15**, 311
Goldschmidt, H., see Egerer, G. **15**, 119
Gómez-Lus, R., see del Campo, R. **15**, 221
Gorla, N., see García Ovando, H. **15**, 77
Gould, I.M., see Mackay, M.L. **15**, 125
Graham, D.Y., see Kwon, D.H. **15**, 31

PII: S0924-8579(00)00166-7

Haas, R., see Egerer, G. **15**, 119
Hamilton-Miller, J.M.T., Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment **15**, 179
Hammerschlag, M.R. and P.M. Roblin, Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to *Chlamydia pneumoniae* **15**, 149
Hammerschlag, M.R., Treatment of *Chlamydia pneumoniae* **15**, 239
Hegenbart, U., see Egerer, G. **15**, 119
Herrera, M., P. Carrión, M. Bravo and A. Castillo, Antibacterial activity of four dentin bonding systems **15**, 305
Herrero, I.A., see Teshager, T. **15**, 137
Hirai, K., see Murakami, J. **15**, 103
Hiramatsu, K., see Murakami, J. **15**, 103
Hirata, K., see Zheng, X. **15**, 231
Ho, A.D., see Egerer, G. **15**, 119
Hoban, D.J., see Jones, R.N. **15**, 111
Hunfeld, K.-P., P. Kraiczy, T.A. Wichelhaus, V. Schäfer and V. Brade, Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against *Borrelia burgdorferi* isolates **15**, 11
Hunter, R.L., see Jagannath, C. **15**, 55

Isaac, L., see Allen, A. **15**, 283
Ito, K., see Shimada, K. **15**, 49

Jacob, L.E., see Udo, E.E. **15**, 19
Jagannath, C., M.R. Emanuele and R.L. Hunter, Activity of poloxamer CRL-1072 against drug-sensitive and resistant strains of *Mycobacterium tuberculosis* in macrophages and in mice **15**, 55
Jenkins, S.G., see Jones, R.N. **15**, 111
Jones, R.N., M.A. Pfaller and M.E. Erwin, Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 Gram-positive pathogens from diverse geographic areas **15**, 227
Jones, R.N., see Deshpande, L. **15**, 271
Jones, R.N., see Marshall, S.A. **15**, 291
Jones, R.N., S.G. Jenkins, D.J. Hoban, M.A. Pfaller and R. Ramphal, In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997–1998 **15**, 111

Kishi, K., see Murakami, J. **15**, 103
Kraiczy, P., see Hunfeld, K.-P. **15**, 11
Krcméry, V. and F. Paradisi, Nosocomial bacterial and fungal meningitis in children; an eight year national survey reporting 101 cases **15**, 143
Krcméry, V., Jr, Systemic chlorellosis, an emerging infection in humans caused by algae **15**, 235
Kuchta, T., see Múčková, M. **15**, 153
Kugler, K.C., see Marshall, S.A. **15**, 291
Kwon, D.H., M.S. Osato, D.Y. Graham and F.A.K. El-Zaatari, Quantitative RT-PCR analysis of multiple genes encoding putative metronidazole nitroreductases from *Helicobacter pylori* **15**, 31

Lacy, M.K., P.R. Tessier, D.P. Nicolau, C.H. Nightingale and R. Quintiliani, Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci **15**, 25
Lauretti, L., see Araque, M. **15**, 37
Lehn, N., see Wagenlehner, F. **15**, 207
Leibovitz, E. and R. Dagan, Antibiotic treatment for acute otitis media **15**, 169
Lerner, D.L., see Torres, C. **15**, 257
Lerner, S.A., see Torres, C. **15**, 257
Lewis, A., see Allen, A. **15**, 283
Liebman, J.A., see Pettit, R.K. **15**, 299
Lubaczewski, L., see Quiroga, M. **15**, 243
Lu, J.-F., see Xuan, D. **15**, 185
Lukova, V., L.S. Tzouvelekis, P.T. Tassios and W. Thiel, Extended spectrum β-lactamases in salmonella strains isolated in Austria **15**, 155

Mackay, M.L., K. Milne and I.M. Gould, Comparison of methods for assessing synergic antibiotic interactions **15**, 125
Marshall, S.A., K.C. Kugler and R.N. Jones, Evaluation of quinupristin/dalfopristin (Synercid®) and RPR 106 972 stability in susceptibility testing media **15**, 291
Mathew, B., see Udo, E.E. **15**, 19
Mattina, R., see Nicoletti, G. **15**, 265
McDaniel, L.S., see Swiatlo, E. **15**, 73
Meis, J.F.G.M., see Ascioglu, S. **15**, 159
Melekos, M.D. and K.G. Naber, Complicated urinary tract infections **15**, 247
Milne, K., see Mackay, M.L. **15**, 125
Mokadas, E.M., see Udo, E.E. **15**, 19
Monnet, D.L., Toward multinational antimicrobial resistance surveillance systems in Europe **15**, 91
Moore, E., see Swiatlo, E. **15**, 73
Moreno, M.A., see Teshager, T. **15**, 137
Múčková, M., H. Bujdáková and T. Kuchta, Synergy between 6-amino-2-*n*-pentylthiobenzothiazole and ergosterol biosynthesis-inhibiting antimycotics against *Candida albicans* in vitro **15**, 153
Muñoz, P., A. Burillo and E. Bouza, Criteria used when initiating antifungal therapy against *Candida* spp. in the intensive care unit **15**, 83
Murai, S., see Shimada, K. **15**, 49
Murakami, J., K. Kishi, K. Hirai, K. Hiramatsu, T. Yamasaki and M. Nasu, Macrolides and clindamycin suppress the release of Shiga-like toxins from *Escherichia coli* O157:H7 in vitro **15**, 103

Naber, K.G., see Melekos, M.D. **15**, 247
Naber, K.G., see Wagenlehner, F. **15**, 207
Nasu, M., see Murakami, J. **15**, 103
Nicolau, D.P., see Lacy, M.K. **15**, 25
Nicolau, D.P., see Xuan, D. **15**, 185
Nicoletti, G., G. Bonfiglio, A. Bartoloni, R. Mattina, P.L. Nicoletti, P. Pecile, R. Rescaldani, M.A. Romeo, G. Russo, O. Savarino, S. Stefani and F. Paradisi, Distribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures from patients in three Italian intensive care units: a 2-year comparison **15**, 265
Nicoletti, P.L., see Nicoletti, G. **15**, 265
Nieves, B., see Araque, M. **15**, 37
Nightingale, C.H., see Lacy, M.K. **15**, 25
Nightingale, C.H., see Xuan, D. **15**, 185
Numazaki, K. and S. Chiba, **15**, 241

Ortega, E., M.A. de Pablo, J.J. Gaforio, A.M. Gallego, C. Alvarez, A. Ruiz-Bravo and G.A. de Cienfuegos, Modification of acquired immunity in BALB/c mice by aztreonam **15**, 193
Osato, M.S., see Kwon, D.H. **15**, 31
Özbakkaloglu, B., see Tünger, Ö. **15**, 131

Paradisi, F., see Krcméry, V. **15**, 143
Paradisi, F., see Nicoletti, G. **15**, 265
Pascual, A., see García, I. **15**, 201
Pecile, P., see Nicoletti, G. **15**, 265
Pegels, E., see Quiroga, M. **15**, 243
Pellerano, M.L., see De Logu, A. **15**, 43
Perea, E.J., see García, I. **15**, 201
Perlin, M.H., see Torres, C. **15**, 257
Pettit, G.R., see Pettit, R.K. **15**, 299
Pettit, R.K., G.D. Cage, G.R. Pettit and J.A. Liebman, Antimicrobial and cancer cell growth inhibitory activities of 3β-acetoxy-17β-(L-prolyl)amino-5α-androstane in vitro **15**, 299

Pfaller, M.A., see Deshpande, L. **15**, 271
Pfaller, M.A., see Jones, R.N. **15**, 111
Pfaller, M.A., see Jones, R.N. **15**, 227
Poloni, G., see García Ovando, H. **15**, 77
Porrero, M., see Teshager, T. **15**, 137
Prieto, G., see García Ovando, H. **15**, 77

Quintiliani, R., see Lacy, M.K. **15**, 25
Quiroga, M., A. Farinati, E. Pegels, L. Lubaczewski and M. Vergara, Rifampicin sub-inhibitory concentrations reduce the expression of haemolysin in *Aeromonas* spp. **15**, 243

Ramphal, R., see Jones, R.N. **15**, 111
Reppun, T., see Zheng, X. **15**, 231
Rescaldani, R., see Nicoletti, G. **15**, 265
Roblin, P.M., see Hammerschlag, M.R. **15**, 149
Rodríguez-Vilanova, F., see Abad, F. **15**, 65
Romeo, M.A., see Nicoletti, G. **15**, 265
Rossolini, G.M., see Araque, M. **15**, 37
Rubio, C., see del Campo, R. **15**, 221
Ruiz-Bravo, A., see Ortega, E. **15**, 193
Russo, G., see Nicoletti, G. **15**, 265

Sacristán, J.A., see Abad, F. **15**, 65
Salwender, H., see Egerer, G. **15**, 119
Sanders, P., see Gnanou, J.C. **15**, 311
Sanyal, S.C., see Udo, E.E. **15**, 19
Savarino, O., see Nicoletti, G. **15**, 265
Scaltrito, M.M., see Sisto, F. **15**, 277
Schäfer, V., see Hunfeld, K.-P. **15**, 11
Schivo, M.L., see De Logu, A. **15**, 43
Schneider-Brachert, W., see Wagenlehner, F. **15**, 207
Shimada, K., K. Ito and S. Murai, A comparison of the bactericidal effects and cytotoxic activity of three types of oxidizing water, prepared by electrolysis, as chemical dental plaque control agents **15**, 49
Siakavellas, E., see Falagas, M.E. **15**, 1
Singh, S., see Zheng, X. **15**, 231
Sisto, F., M.I. Brenciaglia, M.M. Scaltrito and F. Dubini, *Helicobacter pylori*: *ureA*, *cagA* and *vacA* expression during conversion to the coccoid form **15**, 277
Stefani, S., see Nicoletti, G. **15**, 265
Stöwer-Hoffmann, J., see Wagenlehner, F. **15**, 207
Swiatlo, E., E. Moore, J. Watt and L.S. McDaniel, In vitro activity of four fluoroquinolones against clinical isolates of *Pseudomonas aeruginosa* determined by the E test **15**, 73

Tassios, P.T., see Lukova, V. **15**, 155
Tenorio, C., see del Campo, R. **15**, 221
Teshager, T., I.A. Herrero, M. Porrero, J. Garde, M.A. Moreno and L. Domínguez, Surveillance of antimicrobial resistance in *Escherichia coli* strains isolated from pigs at Spanish slaughterhouses **15**, 137
Tessier, P.R., see Lacy, M.K. **15**, 25
Thiel, W., see Lukova, V. **15**, 155
Torres, C., M.H. Perlin, F. Baquero, D.L. Lerner and S.A. Lerner, High-level amikacin resistance in *Pseudomonas aeruginosa* associated with a 3′-phosphotransferase with high affinity for amikacin **15**, 257
Torres, C., see del Campo, R. **15**, 221
Trotti, N., see García Ovando, H. **15**, 77
Tünger, Ö., G. Dinç, B. Özbakkaloglu, Ü.C. Atman and Ü. Algün, Evaluation of rational antibiotic use **15**, 131
Tzouvelekis, L.S., see Lukova, V. **15**, 155

Udo, E.E., E.M. Mokadas, A. Al-Haddad, B. Mathew, L.E. Jacob and S.C. Sanyal, Rapid detection of methicillin resistance in staphylococci using a slide latex agglutination kit **15**, 19

Vaughan, D., see Blondeau, J.M. **15**, 213
Vergara, M., see Quiroga, M. **15**, 243

Wagenlehner, F., J. Stöwer-Hoffmann, W. Schneider-Brachert, K.G. Naber and N. Lehn, Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of *Escherichia coli* to fluoroquinolones in urology **15**, 207
Watase, R., see Zheng, X. **15**, 231
Watt, J., see Swiatlo, E. **15**, 73
Wichelhaus, T.A., see Hunfeld, K.-P. **15**, 11

Xuan, D., J.-F. Lu, D.P. Nicolau and C.H. Nightingale, Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen **15**, 185

Yamasaki, T., see Murakami, J. **15**, 103

Zapater, P., see Abad, F. **15**, 65
Zheng, X., E. Davis, S. Singh, R. Watase, K. Hirata and T. Reppun, Antimicrobial resistance of *Streptococcus pneumoniae*, *Haemophilius influenzae* and *Moraxella catarrhalis* isolated in Hawaii **15**, 231